• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
【24h】

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

机译：苯丁胺/托吡酯可减轻体重并治疗肥胖症中的不良代谢后果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Phentermine hydrochloride is a noradrenergic sympathetic amine approved for decades by the U.S. Food and Drug Administration (FDA) at doses as high as 37.5 mg/day for the short-term treatment of obesity. Topiramate is a sulfamate-substituted monosaccharide marketed since 1996, and approved by the FDA for seizure disorders at doses up to 400 mg/day and for the prevention of migraine headaches at doses up to 100 mg/day. Clinical trial data suggest topiramate promotes weight loss. The prescribing information of neither agent describes adverse drug interactions with the other. The controlled-release formulation of phentermine and topiramate at low, medium and full doses (with full dose containing 15 mg of phentermine hydrochloride and 92 mg of topiramate) promotes weight reduction, with clinical trial data supporting improvement in adiposopathic consequences leading to metabolic diseases. Reported adverse events with this combination agent are as expected, based upon knowledge of the individual components.
机译：盐酸苯丁胺是一种去甲肾上腺素能交感神经胺，已被美国食品和药物管理局（FDA）批准数十年，每天剂量高达37.5 mg，可用于肥胖症的短期治疗。托吡酯是一种氨基磺酸盐取代的单糖，自1996年以来开始销售，并已获得FDA批准，用于剂量高达400毫克/天的癫痫发作和预防剂量高达100毫克/天的偏头痛。临床试验数据表明托吡酯可促进体重减轻。两种药物的处方信息均未描述药物与另一种药物的不良相互作用。低剂量，中等剂量和全剂量（全剂量包含15毫克盐酸芬特明和92毫克托吡酯）的芬特明和托吡酯控释制剂可促进体重减轻，临床试验数据支持改善导致代谢性疾病的脂肪性后果。根据对单个成分的了解，所报告的这种联合用药的不良事件与预期的一样。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号